Uncategorized

Ascentage Pharma announced that it has released updated data from a US study of the company’s novel drug candidate, olverembatinib, in patients with refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.

Antengene Corporation Limited announced that the first patient has been dosed in the Phase I PERFORM trial of ATG-031 for the treatment of patients with advanced solid tumors or B-cell non-Hodgkin’s lymphoma, at The University of Texas MD Anderson Cancer Center, the lead center of the study that also includes three other clinical trial centers

Seagen Inc. announced that clinically meaningful progression-free survival, a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma.

Bristol Myers Squibb announced the first disclosure of primary analysis results from the high-risk, second-line cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi® in patients with relapsed or refractory follicular lymphoma .

MaaT Pharma presented positive results from the Early Access Program in Europe involving 111 patients with steroid-refractory or steroid-dependent gastrointestinal acute graft-versus-host Disease treated with MaaT013, at the 2023 American Society of Hematology Annual Meeting.

Genentech, a member of the Roche Group, announced that new data from its CD20xCD3 T-cell engaging bispecific antibody program, including eight oral presentations, were presented at the 65th American Society of Hematology Annual Meeting & Exposition, December 9-12, 2023.

¿Cuán pesado puede ser un elemento químico? Unos científicos han descubierto que algunas estrellas fueron capaces de producir elementos químicos con números másicos mucho mayores de 260, o sea más pesados que cualquier elemento de la tabla peri …

MorphoSys AG announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology Annual Meeting.

Positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® or SOLIRIS® continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.